Abstract
With the introduction of multitargeted kinase inhibitors (KIs) for the treatment of individuals with radioiodine-refractory differentiated thyroid carcinoma, new patient safety risks have appeared that require extreme caution on the part of all physicians involved in these patients (Carhill et al., J Clin Endocrinol Metab 98:31–42, 2013; Cabanillas et al., Endocr Rev 40:1573–604, 2019). These adverse events range from common toxicities, such as diarrhea and skin rashes, to uncommon events that can occasionally be life-threatening, such as prolongation of QT intervals that can trigger arrhythmias. Those adverse events that are directly related to the concentration of the drug in circulation can be potentiated by concomitant use of other drugs that alter the metabolic clearance or pharmacokinetics of the KI itself. Thus, knowledge of the potential for drug-drug interactions is critical whenever medications are prescribed for a thyroid cancer patient being treated for metastatic disease with a KI. Patient education is also critical, so that the patient is able to alert whomever is prescribing a medication for them to check for possible drug-drug interactions that either increase risk or decrease the effectiveness of the KI.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, et al. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab. 2013;98(1):31–42.
Cabanillas ME, Ryder M, Jimenez C. Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond. Endocr Rev. 2019;40(6):1573–604.
Hussaarts K, Veerman GDM, Jansman FGA, van Gelder T, Mathijssen RHJ, van Leeuwen RWF. Clinically relevant drug interactions with multikinase inhibitors: a review. Ther Adv Med Oncol. 2019;11:1758835918818347.
Ghatalia P, Je Y, Kaymakcalan MD, Sonpavde G, Choueiri TK. QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer. 2015;112:296–305.
Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf. 2013;36(5):295–316.
Thomas-Schoemann A, Blanchet B, Bardin C, Noe G, Boudou-Rouquette P, Vidal M, et al. Drug interactions with solid tumour-targeted therapies. Crit Rev Oncol Hematol. 2014;89(1):179–96.
van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009;35(8):692–706.
Bowlin SJ, Xia F, Wang W, Robinson KD, Stanek EJ. Twelve-month frequency of drug-metabolizing enzyme and transporter-based drug-drug interaction potential in patients receiving oral enzyme-targeted kinase inhibitor antineoplastic agents. Mayo Clin Proc. 2013;88(2):139–48.
Kruse V, Somers A, Van Bortel L, De Both A, Van Belle S, Rottey S. Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions. J Clin Pharm Ther. 2014;39(3):259–65.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Sherman, S.I. (2021). RAI-Refractory, Advanced Differentiated Thyroid Cancer Receiving Kinase Inhibitor Treatment: Checking for Drug-Drug Interactions. In: Grani, G., Cooper, D.S., Durante, C. (eds) Thyroid Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-61919-0_33
Download citation
DOI: https://doi.org/10.1007/978-3-030-61919-0_33
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-61918-3
Online ISBN: 978-3-030-61919-0
eBook Packages: MedicineMedicine (R0)